PDFファイル - 医薬品医療機器総合機構
Contents
1. 2 NCC S 43 9 3 4 4 NCC ST 4 3 9 NCC ST 439 3 0 NCC2. EDTA 1 0 m g m 28 5mg mL 1 0 0U mL 2 F C 19 2mg d 20 1mg d 496mg dL 1 5 0 0 1 1
3. 1 2 50 L NCC ST 4 3 9 2 3 5 0 L ALP NCC S 4 3 9 3 NCC ST 439 5 x 1 1 0 U mL NCC ST 43 9 1 0mLX1 2 5 U mL NCC ST 43 9 1 0mLX1 3 2 5U mL NCC ST 4 3 9 1 0mLX1 4 80U mL NCC ST 4 3 9 1 0mLX1 5 2 0 0U mL NCC ST 4 3 9 1 0mL X1 4 100mLx6 50mLx6 AMP PD 5 1000mLx1 6
4. WQX02T 2012 5 1 22200AMX00293000 NCC ST 439 5T 4 NK 1 2 3 4 5 OR i 6
5. NCC S 4 3 9 3 0 1 2 3 1 0 29 0 0 5 1 E
6. eS ST 439 NCC ST 439 1 1 2 0 2 3 5 6 7 f 4
7. 1 1 NCC ST 4 3 9 5 U mL NCC ST 43 9 0 U mL NCC 2 NCC ST 43 6 0 9 NCC S 4 3 9 n 6 0 r 1 0 0 y 1 02x x y 0 1 4 1 1 HIV HBV HCV 2 pH10
8. NCC ST 439 1 0 0 0 p pm 2 1 2 1C 2 0 5 1000p pm 1 1 2 ST 439 4 2 3 2 0 3 6 CV 1 0 4 1 0 2 0 0U mL
9. 3 6 NCC ST 43 9 1 0 0 N II Le 8 NCC ST 4 3 9 NCC ST 439 AMP PD CLE I A chemiluminescent enzyme immunoassay G1200
10. G1200 0 1U mL 2 1 NCC ST 4 3 9 NCC ST 43 9 1 1 1 ST 439 EI A n 111 r 0 9 9 y 1 08x 0 44 x ST 439 y 2 1 0 1 2 1 0 1 NCC ST 439 2 1 0 1 2 1 0 9 2 1 0 9 2 1 0 9
11. 3 4 2 2 ST 4 3 9 3 4 5 6 NCC ST 439 7 8 9 10 1 3
12. 300mLxX4 80mLx4 1 1 5 2 AMPPD 3 2 spiroadamantane 4 methoxy 4 3 phosphoryloxy pheny 1 2 dioxetane disodium salt 3 2 4 4 3 1 2 2 h NCC ST 43 9 2 NCC ST 4 3 9 lt 2 gt y NCC ST 4 3 9 NCC ST 439 NCC ST 439 NCC ST 439
13. 2 2 NCC ST 43 9 15 25 G1200 100 3 4 1 0 1 5 2 5 1 5 2 5 2 1 2 3 1
14. 780100 ST 439 NK 4 2 2 780124 ST 439 NK 1 4 X3 780117 ST 439 NK 5 x 1 NCC ST 4 3 9 219973 100mLX6 292600 50mLX6 219942 1000mL X1 219935 300mLX4 292617 80mLX4 1 Medical Technology 31 530 531 2003 2 NCC ST 439EIA 14 1901 1906 1987 3 NCC ST 439 35 1233 1238 1987 4 NCC ST 439 16 269 273 20
15. Q i NCC 1 5 2 5 ALP 1
16. 250 L NCC ST 43 9 40xL 2 37 10 NCC ST 439 NCC ST 439 NCC ST 439 25 0 37 10 200L 37C 5 477nm 0
17. ST 439 NCC ST 43 9 2 0 0U mL 1 4 9 7 0 U mL 5 0 4 5 U mL 2 1 2 3
18. 01 5 NCC ST 439 15 71 74 2000 6 Asanuma K et al Tumor marker levels elevate false positively in postsurgical breast cancer patients with high sGPT levels or with receiving oral 5 FU or its derivatives Breast Cancer 6 181 186 1999 7 Hirohashi S et al Monoclonal antibody reactive with the sialyl sugar residue of a high molecular weight glycoprotein in sera of cancer patients Gann 75 485 488 1984 8 Kumamoto K et al Specific detection of Sialyl Lewis X determinant carried on the mucin GlcNAc 8B 1 gt 6GalNAc a core structure as a tumor associated antigen Biochem Biophys Res Commun 247 514 517 1998 9 Nishizono 1 et al Rapid and sensitive chemiluminescent enzyme immunoassay for measuring tumor markers Clinical Chemistry 37 1639 1644 1991 TEL 03 3816 4480 AX 03 3816 6544 9 TBL 03 3237 5225 AX 03 3237 5364 9 LL EL 0120 292 832 FAX 03 5695 9234 lt Se 113 0033 2 38
19. Se Hf 102 8172 2 2 62 5
Download Pdf Manuals
Related Search